课题基金 / 基金详情

Molecular Analysis of the Erythropoietic Stress Response in vivo

Molecular Analysis of the Erythropoietic Stress Response in vivo
体内红细胞生成应激反应的分子分析
批准号:
7198059
负责人:
Merav Socolovsky
金额:
$39.45万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2011-03-31

项目摘要

项目成果

Merav Socolovsky的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):红细胞生成应激反应对于贫血、心肺疾病、化疗和骨髓移植的生存和恢复至关重要。它包括红细胞生成组织的急剧扩张,导致红细胞生成率增加。其主要介质是激素促红细胞生成素,其受体EpoR由红系祖细胞表达。在应激过程中EpoR信号传导的分子靶点在很大程度上是未知的,并且在应激过程中它调节的祖细胞谱没有完全确定。我们的长期目标是阐明红细胞生成应激反应的分子机制。一个主要的障碍是缺乏特定的细胞表面标记物,识别分化阶段特异性红系祖细胞在体内,因为他们正在经历的压力。我们已经开发了一种利用细胞表面CD 71和Ter 119的流式细胞术检测,使我们能够直接在造血组织中识别阶段特异性成红细胞。使用该测定,我们发现EpoR激活的转录因子Stat 5是早期成红细胞存活的关键调节因子。缺乏Stat 5的小鼠是贫血的,并且具有不足的应激反应。因此,我们的主要假设表明,早期成红细胞存活直接调节红细胞生成率和应激反应。目前的建议集中在死亡受体Fas及其配体,FasL。使用流式细胞术的CD 71/Ter 119测定,我们发现,这两种表达的约50%的早期成红细胞在脾脏。Fas表达与早期成红细胞存活率和组织中的频率呈负相关。此外,小鼠的慢性应激或急性Epo给药导致早期成红细胞表面Fas和FasL的下调。我们的具体目标是:(1)研究Fas和FasL在早期成红细胞中的功能。我们将在无自身免疫性溶血的免疫缺陷背景下产生Fas和FasL突变小鼠,以检验早期成红细胞Fas负调控基础红细胞生成的假设。(2)通过比较从小鼠应激模型中新鲜分离的早期成红细胞与从对照小鼠中分离的等效细胞,确定应激期间成红细胞Fas和FasL下调的分子机制。3)我们将使用EpoR和红系特异性Stat 5缺陷小鼠来研究EpoR和Stat 5信号在应激诱导的成红细胞Fas/ FasL下调中的作用。我们还将测试这些小鼠的应激反应缺陷是否在Fas或FasL突变体背景下繁殖时得到拯救。相关性:为了从失血、贫血或骨髓移植和化疗等治疗过程中生存和恢复,我们的身体需要能够以比正常高得多的速度产生红细胞。这项工作旨在了解调节红细胞快速产生的机制。这可能有助于未来治疗贫血,包括贫血和与癌症相关的疲劳。
英文摘要
DESCRIPTION (provided by applicant): The erythropoietic stress response is essential for survival and recovery from anemias, cardio-pulmonary disease, chemotherapy and bone marrow transplantation. It consists of a dramatic expansion in erythropoietic tissue leading to increased erythropoietic rate. Its principal mediator is the hormone erythropoietin, whose receptor, EpoR, is expressed by erythroid progenitors. The molecular targets of EpoR signaling during stress are largely unknown, and the spectrum of progenitors it regulates during stress is not fully defined. Our long-term goal is to elucidate the molecular mechanisms critical to the erythropoietic stress response. A major obstacle had been the lack of specific cell-surface markers identifying differentiation stage-specific erythroid progenitors in vivo as they are undergoing stress. We have developed a flow cytometric assay utilizing cell-surface CD71 and Ter119 that allows us to recognize stage-specific erythroblasts directly in hematopoietic tissue. Using this assay, we found that the EpoR-activated transcription factor Stat5 is a key regulator of early erythroblast survival. Mice lacking Stat5 are anemic and have a deficient stress response. Therefore, our principal hypothesis suggests that early erythroblast survival directly regulates erythropoietic rate and the stress response. The present proposal focuses on the death receptor Fas and its ligand, FasL. Using the flow-cytometric CD71/Ter119 assay, we found that both are expressed by approximately 50% of early erythroblasts in spleen. Fas expression was inversely related to early erythroblast survival and frequency in tissue. Further, chronic stress in mice or acute Epo administration results in down-regulation of Fas and FasL from the early erythroblast cell surface. Our specific aims are: (1) Investigate Fas and FasL function in early erythroblasts in vivo. We will generate Fas and FasL mutant mice on an immune-deficient background free of autoimmune hemolysis, to test the hypothesis that early erythroblast Fas negatively regulates basal erythropoiesis. (2) Identify the molecular mechanisms responsible for down-regulation of erythroblast Fas and FasL during stress, by comparing early erythroblasts freshly isolated from mouse models of stress to equivalent cells isolated from control mice. 3) We will use EpoR and erythroid-specific Stat5-deficient mice to study the role of EpoR and Stat5 signaling in stress-induced erythroblast Fas/ FasL down-regulation. We will also test whether the deficient stress response of these mice is rescued when bred onto a Fas or FasL-mutant background. Relevance: In order to survive and recover from blood loss, anemia, or therapeutic procedures such as bone-marrow transplantation and chemotherapy, our bodies need to be able to generate red blood cells at a much higher rate than normal. The proposed work aims to understand mechanisms regulating the rapid production of red cells. This may contribute to future therapies of anemias, including anemia and fatigue associated with cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EpoR & Stat5 regulation of ribosome biogenesis and protein synthesis in erythropoiesis
Specialized cell cycles in early erythropoiesis
Specialized cell cycles in early erythropoiesis
Specialized cell cycles in early erythropoiesis
国内基金
海外基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
  • 批准号:
    82302715
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    熊泽康
  • 依托单位:
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2021
  • 负责人:
    陈英伟
  • 依托单位:
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
  • 批准号:
    31200592
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2012
  • 负责人:
    孙伟力
  • 依托单位: